Charlie Foucar

RIP 7+3 (1973-2025)? Why PARADIGM Doesn't Deliver the Eulogy. Listen to our take on the #PARADIGM #Plenary from #ASH25 @ajperissinotti @Berninini open.spotify.com/episode/5pO9pc…

Trainees beware🚨Meetings like #ASH25 are high-density environments of social validation and external rewards. Extrinsic goals provide temporary satisfaction, undermine autonomy and have negative psychological effects! Instead focus on intrinsic goals like personal growth, relationships, and community contribution, you will be proud and need no applause.

Our traditional #COMMAND_consortium meetup at #ASH25 — always a highlight. So proud of this incredible group. @Dr_RoryShallis @Anand_88_Patel @AlexColtoff @ChenyuLinMD @CharlieFoucar #Ehab_Atallah #Eric_Winer we missed @YasminAbaza

The new 2025 @ASH_hematology Guidelines for Treating Newly Diagnosed #AMLsm in Older Adults are now online! 🩸🎗️🩸 We provide 9 critical clinical recommendations mirroring real-time practitioner-patient conversations. @SylvesterCancer @BloodAdvances ashpublications.org/bloodadvances/…

ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL ashpublications.org/bloodadvances/… #leusm #APL

LFGooo! The Rise, the Fall, and the Resurrection of Gemtuzumab in AML. Come listen to @Berninini @ajperissinotti @CharlieFoucar and @Anand_88_Patel nerd out! #leusm #gemtuzumab #aml creators.spotify.com/pod/show/wolve…

🚨🚨👉🏾 Latest paper from #COMMAND_consortium in American Journal of Hematology | Blood Research Journal | Wiley Online Library onlinelibrary.wiley.com/doi/10.1002/aj… Led by @AlexandraRojek and @Anand_88_Patel #RWD on outcome of RR CBF AML, allo-HCT should be considered to improve outcome. Venetoclax based therapies are effective. #leusm

Check out this new article led by @AlexandraRojek & @Anand_88_Patel reporting outcomes in R/R CBF-AML previously treated with intensive chemotherapy! onlinelibrary.wiley.com/doi/10.1002/aj…

A master class in BCR::ABL1-like ALL. I learned so much and am humbled by how far we have to go in this disease. pubmed.ncbi.nlm.nih.gov/39217000/

#lobosslamcancer Thanks to the UNM Lobos for hosting us!

@FirasElChaer @UVACancerCenter @MiamiCancerInst Congrats! Thanks for coming to Albuquerque for our conference!

After 5 incredible years at @UVACancerCenter I’m excited to announce that I’m headed to lead the #Leukemia and #MPN Program at @MiamiCancerInst. Grateful for all I’ve accomplished alongside amazing colleagues at UVA—looking forward to the new opportunities ahead at MCI!

Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia ashpublications.org/blood/article-… by Dr. Luskin et al. #leusm #ALL 100% CR. At day 84, 100% of patients achieved complete cytogenetic remission. At day 84, 74% and 26% achieved BCR::ABL1 reverse transcription quantitative polymerase chain reaction <0.1% and <0.01%, respectively.

AML genomic data pooling between 🇺🇸MARROW consortium 🤝 🇲🇽GTLA led by @LugoMd to clarify the meaning of “hispanic” #ASH24. Mexicans working together in both sides of the Rio Bravo (Grande) @NidiaZa07175883 #Leusm

Extremely proud of @BloodCellsByAle who was awarded the David M. Goldenberg CRTI award at #ASH24 for her recognition as a CRTI participant who presented the highest scoring abstract of the international category at #ASH24. The best prize: the tools she has gained along the way

Excited to run into #AMLSM stars @Anand_88_Patel & our own @MadelynBur22 from @AtriumHealthWFB Comprehensive Cancer Center at #ASH24! @AtriumHealth @LevineCancer @WakeCancer @wakeforestmed @UChicagoLeuk @UCCancerCenter @BKRagonMD

#ASH24 Another very productive #ASH for COMMAND consortium. Presenting several abstracts on acute leukemia and myeloid disorders #leusm #mdssm #mpnsm @Anand_88_Patel @yasminabaza1 @Dr_RoryShallis @vamkota @AlexColtoff @CharlieFoucar @ChenyuLinMD et al.

Topline results studying brexu-cel in relapsed B-ALL, now out @JCO_ASCO. My thanks to @LoriMuffly and partners from 30+ centers driven to answer ?s in a rare disease space. More to come. @bshah @MoffittNews @UChicagoHemOnc ascopubs.org/doi/10.1200/JC…

Today is the Lobo Cancer Challenge! More than 1600 people signed up this year to #uniteagainstcancer

Thank you KOAT for highlighting our Allogeneic Stem Cell transplant program and telling Ana's story. There's still time to support the state-of-the-art cancer treatments and research at UNMCCC by signing up for the #LoboCancerChallenge #UniteAgainstCancer koat.com/article/new-me…

The final version of our @e_JHaem paper on intensive chemo strategies in CBF-AML is available! @AlexandraRojek #leusm -3y OS 70% and 3y EFS 51% for entire cohort -IC + GO 3y EFS 50%, IC alone 3y EFS 47%, IC + KIT inhibitor 3y EFS 85% onlinelibrary.wiley.com/doi/10.1002/jh…